EvoEGF-Mol: Evolving Exponential Geodesic Flow for Structure-based Drug Design
Yaowei Jin, Junjie Wang, Cheng Cao, Penglei Wang, Duo An, Qian Shi
ICML 2026 regular
Abstract (source: OpenReview · © authors)
Structure-Based Drug Design (SBDD) aims to discover bioactive ligands. Conventional approaches construct probability paths separately in Euclidean and probabilistic spaces for continuous atomic coordinates and discrete chemical categories, leading to a mismatch with the underlying statistical manifolds. We address this issue by representing molecules using composite exponential-family distributions, where coordinates and categories are represented within a unified natural parameter space to evolve synchronously along exponential geodesics under the Fisher-Rao metric. To avoid the instantaneous trajectory collapse induced by geodesics directly targeting Dirac distributions, we propose Evolving Exponential Geodesic Flow for SBDD (EvoEGF-Mol), which replaces static Dirac targets with dynamically concentrating distributions and is trained with a progressive-parameter-refinement architecture. Our model approaches a reference-level PoseBusters passing rate (93.4%) on CrossDock, demonstrating remarkable geometric precision and interaction fidelity, while achieving superior performance over baseline methods on real-world MolGenBench tasks for bioactive scaffold recovery. Code is available at https://github.com/BLEACH366/EvoEGF-Mol.
Keywords
Metadata from BioTender-max/icml2026-ai-bio (CC0-1.0). Phở does not host any PDF; links point back to the source.
Related
DeCoDe: Decoupling Binding Position and Molecular Conformation in 3D Ligand Diffusion for Structure-Based Drug Design
Julong Yang, Wen Huang, Junhui Chen, Jian Peng
Recent advances in diffusion models show promise for Structure-Based Drug Design (SBDD), which aims to generate 3D ligand molecules that bind tightly to specific protein targets.…
Contrastive Geometric Learning Unlocks Unified Structure- and Ligand-Based Drug Design
Lisa Schneckenreiter, Sohvi Luukkonen, Lukas Friedrich, Daniel Kuhn +1
Structure-based and ligand-based computational drug design have traditionally relied on disjoint data sources and modeling assumptions, limiting their joint use at scale. In this…
Steering Large Language Models through the DMTA Cycle: Structure-Based Drug Design via Knowledge-Driven Bi-Level Thompson Sampling
Xuanning Hu, Hao Tuo, Jinglong Ji, Anchen Li +2
Structure-based drug design (SBDD) can be effectively realized through an iterative refinement via the Design-Make-Test-Analyze (DMTA) cycle, which is a common workflow used by…